Scynexis (SCYX) Short-term Investments (2016 - 2026)
Scynexis' (SCYX) quarterly Short-term Investments came in at $43.6 million in Q2 2026, up 29.12% on a YoY basis from $33.8 million in Q2 2025, and up 92.97% quarter-over-quarter from $22.6 million in Q1 2026.
Analysis
Scynexis (SCYX) Short-term Investments (2016 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Short-term Investments for 11 consecutive years, with $43.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Short-term Investments rose 29.12% year-over-year to $43.6 million; the trailing twelve-month figure through Jun 2026 stood at $43.6 million (up 29.12% YoY), and the FY2025 full-year result was $18.8 million, down 56.6% from the prior year.
- Short-term Investments grew to $43.6 million in Q2 2026 per SCYX's latest filing, from $22.6 million in the prior quarter.
- Across five years, Short-term Investments topped out at $47.0 million in Q2 2024 and bottomed at $18.8 million in Q4 2025.
- Historically, Short-term Investments has averaged $34.1 million across 5 years, with a median of $33.7 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Short-term Investments soared 70.22% in 2024, then plunged 56.6% in 2025.
- Over 5 years, Short-term Investments stood at $27.7 million in 2022, then soared by 45.59% to $40.3 million in 2023, then grew by 7.29% to $43.2 million in 2024, then slumped by 56.6% to $18.8 million in 2025, then jumped by 132.24% to $43.6 million in 2026.
- According to Business Quant data, Short-term Investments over the past three periods registered $43.6 million, $22.6 million, and $18.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 43.60 Mn |
| Mar 31, 2026 | 22.59 Mn |
| Dec 31, 2025 | 18.77 Mn |
| Sep 30, 2025 | 23.13 Mn |
| Jun 30, 2025 | 33.77 Mn |
| Mar 31, 2025 | 33.67 Mn |
| Dec 31, 2024 | 43.25 Mn |
| Sep 30, 2024 | 40.10 Mn |
| Jun 30, 2024 | 47.04 Mn |
| Mar 31, 2024 | 44.76 Mn |
| Dec 31, 2023 | 40.31 Mn |
| Sep 30, 2023 | 44.00 Mn |
| Jun 30, 2023 | 27.64 Mn |
| Mar 31, 2023 | 27.91 Mn |
| Dec 31, 2022 | 27.69 Mn |
| Sep 30, 2022 | 27.47 Mn |
| Jun 30, 2021 | 55,000.00 |
| Mar 31, 2021 | 55,000.00 |
| Sep 30, 2020 | 55,000.00 |
| Jun 30, 2020 | 3.60 Mn |